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myeloablative haploidentical HSCT. All patients received 12
Gy of total body irradiation followed by 2 x 108 CD3þ cells/kg
donor T cells (HSCT step 1). CY 60 mg/kg/d x 2 was given
starting 2 or 3 days after the T cell infusion in the low and
high risk groups respectively. Tacrolimus and MMF were
begun on day -1. A CD 34 selected product was infused on
day 0 (HSCT step 2) with median CD34 doses of 5.8 and 5.2 x
106/kg in the low and high-risk groups respectively.
19 patients with AML (9), ALL (7), MDS (1), and NHL (2)
without disease, and 16 patients with AML (10), ALL (2), MDS
(3), and T cell NHL (1) with active disease at HSCT were
analyzed. A 17th patient in the high risk group died prior to
engraftment and was not fully evaluable. Outcomes for the
low and high risk groups respectively with 2-24 months
follow-up (median of 9 in each group) were: no rejections;
ANC >500: 11 versus 12 days; grades III-IV GVHD: 5.2%
versus 18.7%; mortality from GVHD 0% versus 6.2%; infec-
tious mortality: 0% versus 12.5%; non-infectious regimen-
related mortality: 0% versus 11.7%; mortality from relapse;
5.2% versus 18.7%; Overall survival: 94.8% versus 52.9%. By
day þ28, all patients had achieved CR and >95% donor
marrow chimerism. Compared to our experience with T cell
depleted (TCD) HSCT, improved T and NK cell IR was
observed, although the low risk group had higher median
numbers of T cells. Conversely, higher numbers of CD56bright
NK cells were present in the high risk group.
Compared to TCD approaches at our institution and
others, the 2 step approach allows for stronger early IR with
low infectious mortality in patients without and with active
malignancy at HSCT. IR was more robust in patients without
active disease. IR in the higher risk groupmay be hindered by
less hospitable marrow stroma and a greater baseline
inﬂammation related to the active malignancy and exacer-
bated by the HSCT. The increased rate of signiﬁcant GVHD
and the prominence of NKbright cells, which are strong
producers of cytokines, may reﬂect this higher state of
inﬂammation. In addition, differences in the degree of T cell
eradication by CY, based on T cell responses to malignancy or
the longer period of T cell activation in the high risk regimen,
may account for variations in IR between the groups.
Recognition of the differences in early IR amongst speciﬁc
patient populations may help optimize post HSCT care.
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Disease relapse after allogeneic hematopoietic stem cell
transplantation (HSCT) is the most important cause of
treatment failure. The mechanisms of leukemia relapse after
allogeneic stem cell transplantation remain elusive. Loss of
HLA class I antigens has been associatedwith disease relapse,
tumor progression and metastasis in solid tumors and has
been shown to be the direct consequence of selective pres-
sure mediated by T cells. We aimed to detect if changes in
HLA antigens occurs and is responsible for leukemia relapse.
We reviewed patients who relapsed post allogeneic stem
cell transplantation (allo-HSCT) for acute myeloid leukemia
(AML) or myelodysplastic syndrome and conducted post-
transplantation studies that included morphologic exami-
nation of bone marrow and HLA typing. Donor and recipient
blood specimens, which were collected pre-transplant and
post-relapse, were typed at intermediate- and high-resolu-
tion for HLA-A, -B, -C, -DRB1, and -DQB1 loci. A leukemia-
enriched population was isolated from peripheral blood
using a CD3þ/CD19þ depletion technique using MACs (Mil-
tenyi, Auburns CA). HLA typing was performed for all
samples either prospectively prior to transplantation and on
archived samples at the time of relapse by polymerase chain
reaction (PCR) ampliﬁcation and oligonucleotide hybridiza-
tion using molecular methods. We compared pre-transplant
and post-relapse specimens with the specimen at diagnosis
to evaluate the loss of heterozygosity (LOH) in blasts.
We identiﬁed 71 patients (median age: 51, 18-67; 48%
male)who relapsed after allo-HSCTand had samples stored at
the time of relapse. Sixty one (86%) transplantations were
matched for 10/10 HLA alleles and 10 (14%) for 9/10 alleles.
Eleven patients (15%) underwent transplantation in ﬁrst
remission (CR1), 15 (21%) in CR2, and 45 (63%) patients had
relapsed AML or primary induction failure. Conditioning
regimen consisted of a myeloablative regimen in 46 patients
(65%) and reduce intensity regimen in 25 patients (35%). The
source of stem-cells was peripheral blood in 47 (66%) and
bone marrow in 24 (34%). LOH in relapsed blasts was pre-
sented inonlyonecaseafterHSCT; in thispatientLOHwasalso
observed in the blasts collected in a pre-transplant specimen.
In conclusion, contrasting with the frequent ﬁnding of
LOH in relapse blasts after HSCT in haploidentical trans-
plantation followed by donor T-cell infusion, LOH in relapse
blasts is not common in T cell-replete matched HSCT. LOH
does not appear to be a dominant escape mechanism for
relapse in allogeneic HSCTwith a closely HLAmatched donor.15
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Although non-myelaoblative conditioning regimens have
proven successful in obtaining engraftment and reducing the
toxicity of allogeneic transplant, improvements are still
needed to improve engraftment rates as well as limit the
incidence of graft versus host disease. Methods to improve
engraftment without added toxicity are especially desirable
in the non malignant setting. Agonists of the Gs-coupled
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Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128 S117Adenosine A2A receptor (A2AR) have been reported to
promote T cell tolerance in several in vivo models, particu-
larly in the GVHD setting; however it’s role in engraftment is
unclear. In this study, we examined the ability of an A2AR
agonist to promote engraftment in a murine allogeneic bone
marrow transplantation model. B6D2F1/J recipients were
conditioned with 300 cGy and transplanted 24 hours later
via lateral tail vein infusion with 2106 T-cell depleted bone
marrow cells from C57BL/6J (B6) donor cells (H2kb into H2kb/
d). Recipients received an A2AR agonist orally in a chow
formulation (1000 mg/kg/day) beginning 2weeks before cell
infusion and continuing for 9 weeks post transplantation. A
second cohort also received the A2AR agonist using osmotic
pumps (100 ng/kg/min) placed subcutaneously 48 hours
prior to cell infusion, for 28days post transplantation as well
as orally via the chow for the same time as the ﬁrst group. A
non-treatment transplant group was used as a control.
There was no apparent toxicity from the radiation or the
drug, and all animals maintained normal blood counts
throughout. Engraftment was observed in only the A2AR
agonist treated groups and a 13 fold higher level of engraft-
ment in themice treated both subcutaneously and orally was
observed. This engraftment appeared to be long term as the
mice were followed out 5 months post transplant with all
mice surviving.
As a possible mechanism of this effect, we measured the
level of CXCR4 expression on the donor bone marrow cells
(Lin-) in vitro and observed that A2AR agonist (10 mM) treat-
ment increased CXCR4 expression 1.6 fold compared to non-
treatment on donor cells in vitro. To further investigate the
effect of the A2AR agonist on engraftment, we are now
repeating the same type of transplant using an A2AR Knock
out mouse strain as the donor. We are also assessing the
levels of SDF-1 in the serum of the recipients.
These preliminary results demonstrate that A2AR agonists
may improve engraftment by increasing homing of the donor
cells without increasing the risk of graft versus host disease
and may be a signiﬁcant addition to transplant regimens.
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18-30 43% 2.95 80% 8.54
31-40 39% 2.88 0.188 80% 8.15 0.002
41-50 32% 2.83 0.052 75% 7.66 < 0.0001
51-60 25% 2.96 0.906 72% 6.78 < 0.0001
18-60 (M) 42% 2.84 85% 8.54
18-60 (F) 35% 3.05 0.004 65% 7.59 < 0.000116
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Background: Be The Match Registry facilitated over 3,300
peripheral blood stem cell (PBSC) transplants and over 1,000
bone marrow (BM) transplants in 2011. The dose of CD34þ
cells for PBSC and total nucleated cell (TNC) count for BM
impact engraftment after unrelated allogeneic transplant.
This study was performed to evaluate the frequency of
unrelated donor PBSC and BM collections that meet the
transplant physician’s requested dose and the role of the
potential donor factors including age and gender.
Methods: A cohort of 1,020 BM and 3,469 PBSC collections
from June 2011 through September 2012 were analyzed to
compare whether the collected cell dose achieved therequested dose. Male and female donors were stratiﬁed in
age groups according to their age at the time of collection
(18-30, 31-40, 41-50, 51þ) and assessed for the frequency
their donated product met the requested cell dose and the
number of cells collected per kg of donor weight.
Results: Of 1,020 BM collections analyzed, a median cell dose
of 5.0 x 10
ˇ
8 TNC/kgwas requestedwith amedian cell dose of
4.2 x 10
ˇ8 TNC/kg collected, resulting in 403 (39.5%) meeting
the requested TNC dose. Of 3,469 PBSC collections, a median
cell dose of 5.0 x 10
ˇ6 CD34þ/kg was requested with
a median cell dose of 8.1 x 10
ˇ6 CD34þ/kg collected, resulting
in 2,740 (79.0%) meeting the requested CD34þ dose.
Increasing donor age resulted in a reduction of the donor’s
ability to supply the requested dose for both PBSC and BM
collections. A statistically signiﬁcant reduction in the number
of cells collected per kg of donor weight was observed for
PBSC collections, but not BM collections (Table 1). In
addition, male donors met the requested cell dose more
frequently than female donors for both BM (42% vs 35%)
and PBSC (85% vs 65%) collections, as well as providing
a signiﬁcantly larger CD34þ cells/kg donor weight for PBSC
(8.54 vs 7.59).
Conclusions: This study shows that younger donor age
results in an increased likelihood of meeting the transplant
physician’s requested TNC or CD34þ dose. Lower donor age
also increases the CD34þ cells/kg that are obtained from
PBSC collections but not the TNC/kg obtained from marrow
collections. In addition, male donors provided increased
CD34þ cells/kg donor weight than female donors. Transplant
center practice is often to select young male donors for
patients, and this data provides evidence to support that
such practice may increase the likelihood of a providing
a product meeting a center’s request.17
Novel Reduced Toxicity Conditioning Regimen for Older
Severe Thalassemia Patients: Sequential Immunoablative
Concept
Suradej Hongeng 1, Samart Pakakasama 2,
Usanarat Anurathapan 3. 1 Pediatrics, Ramathibodi Hospital,
Mahidol University, Bangkok, Thailand; 2 Pediatrics
(Hematology), Ramathibodi Hospital, Bangkok, Thailand;
3 Baylor College of Medicine, Texas Children’s Hospital, The
Methodist Hospital, Houston, TX
CIBMTR reported that severe thalassemia patients older
than 7 years with hepatomegaly (> 2 cm below costal
margin) achieved poor outcome after transplant; DFS ¼ 55%
since they had high rejection and mortality rates (Blood,
2011). We therefore developed the novel reduced toxicity
conditioning (RTC) regimen to overcome these problems.
Fifteen severe thalassemia patients, median age 17 years;
